Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$2.70 (+0.37%) as of
Key statistics
- Market cap
- 1.51B
- P/E (TTM)
- 6.14
- EPS (TTM)
- 0.440
- Dividend yield
- 0.00%
- 52-week range
- 1.820 – 3.000
- Beta
- 0.29
- Revenue (TTM)
- 898.05M
- Profit margin
- 24.36%
- Volume
- 16.00k
About Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products under the Changlong and Qing Tong brands in the People's Republic of China. The company provides Edaravone injection, compound brain comfort capsules, haikun kidney capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets. It also engages in the manufacture and distribution of beverages and prepackaged food, as well as health products. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Kowloon, Hong Kong
- Employees
- 1,107
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.